Albiglutide

Albiglutide is a glucagon-like peptide-1 receptor agonist, a class of injectable diabetes medicines known as incretin mimetics that copy the action of the gut hormone GLP-1 ^[1][2]. Its structure is distinctive: two linked copies of a modified fragment of human GLP-1 are fused to human albumin, the most abundant protein in blood ^[1]. This albumin fusion makes the molecule resistant to the enzyme that normally breaks down GLP-1 within minutes and gives it a half-life of several days, long enough to allow convenient once-weekly injection ^[1].

The drug was used to improve blood sugar control in adults with type 2 diabetes, and clinical studies showed it produced meaningful reductions in the long-term glucose marker HbA1c, though head-to-head comparisons found it somewhat less potent for lowering blood sugar and body weight than some other GLP-1 receptor agonists such as liraglutide ^[2]. A large cardiovascular outcomes trial known as Harmony Outcomes later showed that, in people with type 2 diabetes and existing heart disease, once-weekly albiglutide reduced the risk of major cardiovascular events such as heart attack and stroke compared with placebo ^[3]. Its large, albumin-bound structure limited its entry into the brain, which is thought to explain its relatively modest effect on appetite and weight compared with smaller agents in the class ^[2].

Albiglutide was developed by GlaxoSmithKline, building on technology from Human Genome Sciences, and was approved in the United States and Europe in 2014 under the names Tanzeum and Eperzan ^[2]. Despite favorable trial results, the manufacturer withdrew it from markets worldwide in 2018, citing limited commercial prospects rather than any safety problem, which has made it largely unavailable since ^[2]. It is administered by subcutaneous injection and belongs to a drug class that remains widely used for diabetes and, increasingly, for weight management ^[2].

The most common side effects were gastrointestinal, like nausea and diarrhea, plus injection-site reactions which were more common than with some other GLP-1 drugs. As a class, GLP-1 agonists carry a warning about thyroid C-cell tumors seen in rodents and a risk of pancreatitis. It should not be used by people with a history of medullary thyroid cancer or MEN 2.